Tag

Obesity Drugs

All articles tagged with #obesity drugs

health16 days ago•5 min saved

Medicare Opens Obesity-Drug Access for Seniors, Yet Awareness Is Lagging

Medicare’s Bridge demonstration program will start covering obesity medications for eligible beneficiaries with a $50 monthly copay, starting July 1, expanding access to GLP-1 drugs like Wegovy and Zepbound; however, awareness among seniors is low, enrollment isn’t automatic and requires a prescription plus prior authorization, and public outreach is being scaled up after launch as CMS and drugmakers prepare for possible demand through 2027.

via CNBC|

#bridge-program #glp-1 #health

health29 days ago•6 min saved

GLP-1 obesity drugs show early signs of boosting testosterone and sperm quality

A preliminary synthesis of trials and health‑record data suggests GLP‑1 obesity drugs may raise testosterone and improve sperm quality in men with obesity, but findings are mixed and need confirmation: some studies show testosterone increases, others show no change; one trial found GLP‑1 boosted testosterone while TRT increased it more and reduced sperm quality; a Mayo Clinic analysis observed about a 30% testosterone rise with GLP‑1–type therapies. More robust trials are needed.

via Nature|

#fertility #glp-1 #health

business1 month ago•15 min saved

Next-gen obesity drug race tightens as pivotal readouts loom

Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.

via Pharma Voice|

#business #eli-lilly #glp-1

business2 months ago•2 min saved

Novo Nordisk Signals Aggressive Hunt for Deals to Expand GLP-1 Pipeline

Novo Nordisk CEO says the company is actively pursuing acquisitions to broaden its GLP-1 pipeline amid growing competition in obesity drugs, citing assets like CagriSema and zenagamtide; Wegovy's strong Q1 performance lifted full-year guidance, even as Eli Lilly overtook Novo in weekly GLP-1 market share.

via CNBC|

#acquisitions #business #glp-1

business2 months ago•5 min saved

Wegovy Drive Lifts Novo Nordisk's 2026 Guidance

Novo Nordisk raised its 2026 guidance after a strong Q1 powered by Wegovy, with U.S. Wegovy prescriptions around 1.3 million and Wegovy sales of 2.26 billion DKK; first-quarter sales rose 32% cc to 96.8 billion DKK and reported operating profit jumped 65%, though adjusted sales fell 4% and adjusted profit fell 6% excluding a $4.2 billion 340B-related adjustment. The company plans to launch Wegovy outside the U.S. in H2 2026, and the stock rose intraday but closed at a new five-year low amid competition in the GLP-1 weight-loss market.

via CNBC|

#business #earnings #glp-1

business2 months ago•2 min saved

Kailera IPO shines as GLP-1 doubts spark interest in GIP-glucagon obesity strategy

Kailera Therapeutics raised $625 million in an IPO—the largest ever for a drug company—while researchers question the necessity of GLP-1 for obesity therapy and consider GIP-glucagon as a potentially better, more tolerable dual target; the Readout also notes FDA interest in expanding testosterone therapy for libido.

via statnews.com|

#business #gip-glucagon #glp-1

business2 months ago•4 min saved

Kailera’s $625M IPO Redefines Biotech Financing for Obesity Drugs

Kailera Therapeutics upsized its IPO to $625 million (39 million shares at up to $16), becoming the largest biotech IPO in recent memory and funding its obesity-focused GLP-1 program (ribupatide) along with other assets; shares trade on Nasdaq as KLRA, with a potential $92.8 million greenshoe. CEO Ron Renaud says the momentum isn’t changing the strategy, and the funds will back three global phase 3 trials through 2028 as Kailera expands its obesity portfolio.

via Fierce Biotech|

#biotech-ipo #business #glp-1

market-news3 months ago•16 min saved

HSBC Downgrades Lilly as Obesity Market Faces Pricing Pressures

HSBC analyst Rajesh Kumar downgraded Eli Lilly (LLY) from Hold to Sell, arguing that pricing dynamics and a downsized total addressable market, intensified competition from Novo Nordisk, and potential headwinds for Lilly’s oral obesity drug orforglipron could limit upside; he cut the price target from $1,070 to $850 as TAM is viewed at about $80–120B versus consensus around $150B+, while the broader market remains bullish with a Strong Buy consensus and ~36% upside over the next year.

via TipRanks|

#healthcare #lly #market-news

science3 months ago•2 min saved

Snake metabolite pTOS hints at a new appetite-control drug path

Researchers identified pTOS, a metabolite produced by python gut bacteria that surges after a meal (more than 1,000-fold); when given to obese mice, it suppressed appetite, leading to about 9% body weight loss over 28 days, without notable changes in energy expenditure or organ size. Unlike GLP-1 drugs that slow gastric emptying, pTOS appears to act on the hypothalamus to regulate hunger. The molecule also exists at low levels in human urine, suggesting potential safety, though clinical applicability requires more research; the findings were published in Nature Metabolism.

via The Guardian|

#appetite-regulation #gut-microbiome #hypothalamus

health3 months ago•5 min saved

Most weight lost on GLP-1 obesity drugs returns within a year, study finds

A meta-analysis of six randomized trials (3,200+ participants) shows people rapidly regain about 60% of the weight lost during GLP-1 class obesity treatments within a year of stopping, with long-term modelling suggesting regain may plateau after around 60 weeks and reach roughly 75% of the lost weight. The studies raise uncertainty about whether regained weight is lean mass or fat, and they underscore the potential need for tapering doses and lifestyle support to preserve fat loss after cessation.

via ScienceAlert|

#glp-1 #health #obesity-drugs

business4 months ago•2 min saved

Hims & Hers stock leaps on Novo Nordisk obesity-drug partnership talks via telehealth

Hims & Hers Health Inc. shares jumped in premarket trading after media reports that Novo Nordisk plans to sell obesity drugs through Hims & Hers' telehealth platform as part of a potential partnership between the two companies.

via Seeking Alpha|

#business #hims-and-hers-health #novo-nordisk

health4 months ago•5 min saved

GLP-1 obesity drugs linked to lower addiction risk in a massive VA study

A large observational study of electronic health records from over 600,000 US veterans found that GLP-1 drugs used for obesity and type 2 diabetes were associated with reduced risk of developing substance-use disorders and, among those with addiction, about a 50% lower risk of death from substance abuse. Among GLP-1 users with no prior addiction, three-year risks were 18% lower for alcohol, 14% lower for cannabis, 20% lower for cocaine, 20% lower for nicotine, and 25% lower for opioids compared with users of another diabetes medication, though randomized trials are needed to establish causality.

via Nature|

#addiction #glp-1 #health

business4 months ago•3 min saved

Lilly Launches Employer Connect to Expand Employer Coverage for Obesity Drugs

Eli Lilly unveils Employer Connect to help employers cover obesity medicines by connecting them with 15+ program administrators and offering a net price of $449 per month for a new Zepbound dose, aiming to lower employee out-of-pocket costs while giving employers design flexibility and price visibility; the move comes as Medicare coverage for these drugs is set to expand later this year and some firms may opt in gradually.

via CNBC|

#business #employer-coverage #glp-1

health4 months ago•6 min saved

GLP-1 obesity drugs and pancreatitis: what the science actually shows

Regulators in the UK and Brazil warned of a possible link between GLP-1 weight‑loss drugs and pancreatitis, but causality remains unclear. With millions using GLP-1 therapies for obesity and related conditions, reported pancreatitis cases and deaths are very rare relative to use (UK: 19 pancreatitis deaths since 2007 and about 1,300 related reports among ~1.6 million users; Brazil: 6 deaths and 145 pancreatitis cases since 2020). Meta-analyses yield mixed results—some show a small risk, others none—while a large real‑world study found no difference in pancreatitis between GLP‑1 users and non‑users with similar risk factors. Ongoing pharmacovigilance and rigorous studies are needed to distinguish true signals from background risk.

via Nature|

#clinical-trials #glp-1 #health

politics5 months ago•5 min saved

TrumpRx: White House rolls out cash-pay drug hub to lower costs

The White House announced TrumpRx, a direct-to-consumer hub that directs cash-paying patients to discounts offered by drugmakers on their own sites, as part of efforts to lower U.S. prescription costs. The site does not sell drugs itself and may not benefit insured patients who rely on coverage, but could help uninsured or underinsured access drugs not widely covered, such as obesity medications; participating makers include Lilly and Novo Nordisk, with prices advertised (e.g., Ozempic and Wegovy at about $350/month) amid broader debated savings, since actual prices often depend on rebates and payer contracts. The overall impact on out-of-pocket costs remains uncertain.

via CNBC|

#direct-to-consumer #discounts #drug-pricing